aid: delphia-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/delphia-therapeutics.png
name: Delphia Therapeutics
description: 'Delphia Therapeutics is a Cambridge, Massachusetts oncology biotechnology company pioneering
  "activation lethality," a precision-medicine approach that targets cancer cells'' vulnerability to
  oncogene overactivation by selectively over-activating cancer-linked signaling until tumor cells can
  no longer survive. Founded by oncology drug developers Kevin Marks, Bill Sellers, and Mike Dillon,
  the company launched with a $67 million Series A financing led by GV, with participation from Nextech
  Invest, Polaris Innovation Fund, and Alexandria Venture Investments. Delphia is a preclinical-stage
  drug developer and does not currently publish a public developer API, SDK, or developer portal.'
url: https://raw.githubusercontent.com/api-evangelist/delphia-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Oncology
- Biotechnology
- Cancer
- Precision Medicine
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/delphia-therapeutics-domain-security.yml
- type: Website
  url: https://www.delphiatx.com
- type: PrivacyPolicy
  url: https://www.delphiatx.com/privacy-policy/
- type: Blog
  url: https://www.delphiatx.com/news/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence